Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Glioblastoma 31Gliosarcoma 27Astrocytoma 22Brain Neoplasms 17Central Nervous System Neoplasms 16Oligodendroglioma 12Medulloblastoma 9Neuroblastoma 7Glioma 7Choroid Plexus Neoplasms 7Sarcoma 6Melanoma 6Familial ependymoma 6Optic Nerve Glioma 5Spinal Cord Neoplasms 4Rhabdoid Tumor 4Neuroectodermal Tumors, Primitive, Peripheral 4Ependymoma 4Uveal Melanoma 3Rhabdomyosarcoma 3Ovarian Neoplasms 3Osteosarcoma 3Neuroectodermal Tumors, Primitive 3Breast Neoplasms 3Wilms Tumor 2Testicular Neoplasms 2Teratoma 2Small Cell Lung Carcinoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pinealoma 2

Interventions

pazopanib 1Vorinostat 1Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Paraganglioma, Extra-Adrenal × Temozolomide × Clear all
NCT01076530 2013-05-03

Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
CNSEndocrine

Familial ependymoma, Astrocytoma, Medulloblastoma, Oligodendroglioma, Paraganglioma, Extra-Adrenal, Spinal Cord Neoplasms, Choroid Plexus Neoplasms, Rhabdoid Tumor, Optic Nerve Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡